Trial Profile

A pivotal trial investigating docetaxel emulsion [ANX 514; Adventrx Pharmaceuticals] without corticosteriod premedication, compared with docetaxel [Taxotere; sanofi-aventis] with corticosteroid premedication, in patients with non-small cell lung cancer that has failed prior platinum-based therapy.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Oct 2011 ADVENTRX and the US FDA have met to discuss the trial, and agree that it will provide sufficient clinical data to support approval of the docetaxel emulsion (ANX 514), according to an ADVENTRX media release. The company expects to fline and NDA in 2014.
03 Oct 2011 Planned initiation date changed to 1 Jan 2012, according to an ADVENTRX Pharmaceuticals media release.
28 Mar 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com